NCT02946554View on ClinicalTrials.gov

Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2020

Conditions
Acute-On-Chronic Liver Failure
Interventions
BIOLOGICAL

HepaStem

Trial Locations (10)

1020

CHU Brugmann, Brussels

1070

Hôpital Erasme, Brussels

1200

Cliniques St Luc, Woluwe-Saint-Lambert

2650

UZ Antwerpen, Edegem

3000

KU Leuven, Leuven

4000

CHU de Liège, Liège

9000

UZ Gent, Ghent

69004

Hôpital de la Croix Rousse, Lyon

92110

Hôpital Beaujon, Clichy

94804

Hôpital Paul Brousse, Villejuif

Sponsors

Lead Sponsor

Cellaion SA
All Listed Sponsors
lead

Cellaion SA

INDUSTRY